NCT07051031View on ClinicalTrials.gov

COVID-19 Reactogenicity

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

1,000

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

June 30, 2028

Conditions

Compare Post Vaccination Reactions

Interventions

DRUG

Nuvaxovid (NVX-CoV2705)

COVID-19 vaccination

DRUG

Pfizer-BioNTech COVID-19 vaccine

COVID-19 vaccination

Trial Locations (1)

97239

Oregon Health and Sciences University, Portland

All Listed Sponsors

lead

Marcel Curlin

OTHER